The New Profile of Drug-Resistant Tuberculosis in Russia A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science (2011) / Chapter Skim
Currently Skimming:
1 Introduction
1 Introduction
Pages 1-8
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
. TB is the leading killer of people with HIV, and it is also a disease of poverty -- the vast majority of TB deaths occur in the developing world (WHO, 2010a)
|
From page 2... ...
. Workshop participants noted that the rapid spread of drug-resistant forms of TB poses new challenges to effective control of this disease, as diagnosing and effectively treating MDR/ XDR TB patients requires increasingly complex public health interventions.
|
From page 3... ...
Extensively drug-resistant tuberculosis (XDR TB) is resistant to the same drugs as MDR TB (isoniazid and rifampicin)
|
From page 4... ...
. Data on the burden of XDR TB are even more limited because many countries lack the laboratory and infrastructure capacity necessary to test MDR TB patients routinely for susceptibility of their infection to secondline drugs.
|
From page 5... ...
Specifically, the workshop was designed to: • i ncrease awareness and create a renewed sense of urgency with respect to the growing global burden of MDR and XDR TB and its profile in Russia; • c onsider the magnitude of transmission of drug-resistant strains and options for control of transmission and infection; • a ddress the MDR TB burden in vulnerable populations, including children, those coinfected with HIV, and substance abusers; • a ssess current treatment options and approaches to patient care, taking into account the unique needs of the population being treated; • d iscuss the supply of quality-assured second-line TB drugs and the pipeline for a new "cocktail" of TB drugs; • a ssess the current state of the art for rapid detection of drug resis tance and the implications for patient management; and
|
From page 6... ...
It is estimated that only 10 percent of new MDR TB cases are treated each year, and fewer than 2 percent of patients are receiving verifiable, quality-assured second-line anti-TB drugs. Cassell stressed that, among the small population of patients receiving treatment, many are not receiving drugs that actually address their drug resistance profile, and therefore their treatment is ineffective.
|
From page 7... ...
; • t he development of new methods for diagnosing drug-resistant TB in patients, as well as the need for improved laboratory capacity (Chapter 5) ; • t reatment of drug-resistant TB, including TB and HIV coinfection and innovative research on MDR TB treatment (Chapter 6)
|
From page 8... ...
Finally, Chapter 10 looks back at the major viewpoints expressed at the workshop and looks forward to next steps suggested by workshop participants.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.